Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 462 entries
Sorted by: Best Match Show Resources per page
Correction to "Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators".

Journal of medicinal chemistry

Zimmerman SS, Khatri A, Garnier-Amblard EC, Mullasseril P, Kurtkaya NL, Gyoneva S, Hansen KB, Traynelis SF, Liotta DC.
PMID: 25738634
J Med Chem. 2015 Mar 26;58(6):2862. doi: 10.1021/acs.jmedchem.5b00199. Epub 2015 Mar 04.

No abstract available.

Cite
Zimmerman SS, Khatri A, Garnier-Amblard EC, et al. Correction to "Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators". J Med Chem. 2015;58(6):2862doi: 10.1021/acs.jmedchem.5b00199.
Zimmerman, S. S., Khatri, A., Garnier-Amblard, E. C., Mullasseril, P., Kurtkaya, N. L., Gyoneva, S., Hansen, K. B., Traynelis, S. F., & Liotta, D. C. (2015). Correction to "Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators". Journal of medicinal chemistry, 58(6), 2862. https://doi.org/10.1021/acs.jmedchem.5b00199
Zimmerman, Sommer S, et al. "Correction to "Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators"." Journal of medicinal chemistry vol. 58,6 (2015): 2862. doi: https://doi.org/10.1021/acs.jmedchem.5b00199
Zimmerman SS, Khatri A, Garnier-Amblard EC, Mullasseril P, Kurtkaya NL, Gyoneva S, Hansen KB, Traynelis SF, Liotta DC. Correction to "Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators". J Med Chem. 2015 Mar 26;58(6):2862. doi: 10.1021/acs.jmedchem.5b00199. Epub 2015 Mar 04. PMID: 25738634; PMCID: PMC4415028.
Copy Download .nbib Format: NLM
New melanocortin-like peptide of .

NPJ biofilms and microbiomes

Qiang X, Liotta AS, Shiloach J, Gutierrez JC, Wang H, Ochani M, Ochani K, Yang H, Rabin A, LeRoith D, Lesniak MA, Böhm M, Maaser C, Kannengiesser K, Donowitz M, Rabizadeh S, Czura CJ, Tracey KJ, Westlake M, Zarfeshani A, Mehdi SF, Danoff A, Ge X, Sanyal S, Schwartz GJ, Roth J.
PMID: 29152323
NPJ Biofilms Microbiomes. 2017 Nov 13;3:31. doi: 10.1038/s41522-017-0039-9. eCollection 2017.

No abstract available.

Cite
Qiang X, Liotta AS, Shiloach J, et al. New melanocortin-like peptide of . NPJ Biofilms Microbiomes. 2017;3:31doi: 10.1038/s41522-017-0039-9.
Qiang, X., Liotta, A. S., Shiloach, J., Gutierrez, J. C., Wang, H., Ochani, M., Ochani, K., Yang, H., Rabin, A., LeRoith, D., Lesniak, M. A., Böhm, M., Maaser, C., Kannengiesser, K., Donowitz, M., Rabizadeh, S., Czura, C. J., Tracey, K. J., Westlake, M., Zarfeshani, A., Mehdi, S. F., Danoff, A., Ge, X., Sanyal, S., Schwartz, G. J., & Roth, J. (2017). New melanocortin-like peptide of . NPJ biofilms and microbiomes, 331. https://doi.org/10.1038/s41522-017-0039-9
Qiang, Xiaoling, et al. "New melanocortin-like peptide of ." NPJ biofilms and microbiomes vol. 3 (2017): 31. doi: https://doi.org/10.1038/s41522-017-0039-9
Qiang X, Liotta AS, Shiloach J, Gutierrez JC, Wang H, Ochani M, Ochani K, Yang H, Rabin A, LeRoith D, Lesniak MA, Böhm M, Maaser C, Kannengiesser K, Donowitz M, Rabizadeh S, Czura CJ, Tracey KJ, Westlake M, Zarfeshani A, Mehdi SF, Danoff A, Ge X, Sanyal S, Schwartz GJ, Roth J. New melanocortin-like peptide of . NPJ Biofilms Microbiomes. 2017 Nov 13;3:31. doi: 10.1038/s41522-017-0039-9. eCollection 2017. PMID: 29152323; PMCID: PMC5684143.
Copy Download .nbib Format: NLM
Teamwork education improves trauma team performance in undergraduate health professional students.

Journal of educational evaluation for health professions

Baker VO, Cuzzola R, Knox C, Liotta C, Cornfield CS, Tarkowski RD, Masters C, McCarthy M, Sturdivant S, Carlson JN.
PMID: 26101404
J Educ Eval Health Prof. 2015 Jun 25;12:36. doi: 10.3352/jeehp.2015.12.36. eCollection 2015.

PURPOSE: Effective trauma resuscitation requires efficient and coordinated care from a team of providers; however, providers are rarely instructed on how to be effective members of trauma teams. Team-based learning using Team Strategies and Tools to Enhance Performance and...

Cite
Baker VO, Cuzzola R, Knox C, et al. Teamwork education improves trauma team performance in undergraduate health professional students. J Educ Eval Health Prof. 2015;12:36doi: 10.3352/jeehp.2015.12.36.
Baker, V. O., Cuzzola, R., Knox, C., Liotta, C., Cornfield, C. S., Tarkowski, R. D., Masters, C., McCarthy, M., Sturdivant, S., & Carlson, J. N. (2015). Teamwork education improves trauma team performance in undergraduate health professional students. Journal of educational evaluation for health professions, 1236. https://doi.org/10.3352/jeehp.2015.12.36
Baker, Valerie O'Toole, et al. "Teamwork education improves trauma team performance in undergraduate health professional students." Journal of educational evaluation for health professions vol. 12 (2015): 36. doi: https://doi.org/10.3352/jeehp.2015.12.36
Baker VO, Cuzzola R, Knox C, Liotta C, Cornfield CS, Tarkowski RD, Masters C, McCarthy M, Sturdivant S, Carlson JN. Teamwork education improves trauma team performance in undergraduate health professional students. J Educ Eval Health Prof. 2015 Jun 25;12:36. doi: 10.3352/jeehp.2015.12.36. eCollection 2015. PMID: 26101404; PMCID: PMC4536358.
Copy Download .nbib Format: NLM
Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.

Frontiers in pharmacology

Romano A, Giallongo C, La Cava P, Parrinello NL, Chiechi A, Vetro C, Tibullo D, Di Raimondo F, Liotta LA, Espina V, Palumbo GA.
PMID: 28491035
Front Pharmacol. 2017 Apr 26;8:204. doi: 10.3389/fphar.2017.00204. eCollection 2017.

Azacytidine (5-AZA) is the standard first-choice treatment for high-risk myelodysplasia (MDS) patients. However, the clinical outcome for those patients who interrupt treatment or whose disease failed to respond is very poor. In order to identify the cellular pathways that...

Cite
Romano A, Giallongo C, La Cava P, et al. Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia. Front Pharmacol. 2017;8:204doi: 10.3389/fphar.2017.00204.
Romano, A., Giallongo, C., La Cava, P., Parrinello, N. L., Chiechi, A., Vetro, C., Tibullo, D., Di Raimondo, F., Liotta, L. A., Espina, V., & Palumbo, G. A. (2017). Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia. Frontiers in pharmacology, 8204. https://doi.org/10.3389/fphar.2017.00204
Romano, Alessandra, et al. "Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia." Frontiers in pharmacology vol. 8 (2017): 204. doi: https://doi.org/10.3389/fphar.2017.00204
Romano A, Giallongo C, La Cava P, Parrinello NL, Chiechi A, Vetro C, Tibullo D, Di Raimondo F, Liotta LA, Espina V, Palumbo GA. Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia. Front Pharmacol. 2017 Apr 26;8:204. doi: 10.3389/fphar.2017.00204. eCollection 2017. PMID: 28491035; PMCID: PMC5405131.
Copy Download .nbib Format: NLM
The Ecstasy and Agony of Assay Interference Compounds.

ACS medicinal chemistry letters

Aldrich C, Bertozzi C, Georg GI, Kiessling L, Lindsley C, Liotta D, Merz KM, Schepartz A, Wang S.
PMID: 28435522
ACS Med Chem Lett. 2017 Feb 28;8(4):379-382. doi: 10.1021/acsmedchemlett.7b00056. eCollection 2017 Apr 13.

No abstract available.

Cite
Aldrich C, Bertozzi C, Georg GI, et al. The Ecstasy and Agony of Assay Interference Compounds. ACS Med Chem Lett. 2017;8(4):379-382doi: 10.1021/acsmedchemlett.7b00056.
Aldrich, C., Bertozzi, C., Georg, G. I., Kiessling, L., Lindsley, C., Liotta, D., Merz, K. M., Schepartz, A., & Wang, S. (2017). The Ecstasy and Agony of Assay Interference Compounds. ACS medicinal chemistry letters, 8(4), 379-382. https://doi.org/10.1021/acsmedchemlett.7b00056
Aldrich, Courtney, et al. "The Ecstasy and Agony of Assay Interference Compounds." ACS medicinal chemistry letters vol. 8,4 (2017): 379-382. doi: https://doi.org/10.1021/acsmedchemlett.7b00056
Aldrich C, Bertozzi C, Georg GI, Kiessling L, Lindsley C, Liotta D, Merz KM, Schepartz A, Wang S. The Ecstasy and Agony of Assay Interference Compounds. ACS Med Chem Lett. 2017 Feb 28;8(4):379-382. doi: 10.1021/acsmedchemlett.7b00056. eCollection 2017 Apr 13. PMID: 28435522; PMCID: PMC5392755.
Copy Download .nbib Format: NLM
Grasping forceps assisted endoloop/snare polypectomy of a giant duodenal hamartoma.

Therapeutic advances in gastroenterology

Curcio G, Ligresti D, Granata A, Tarantino I, Barresi L, Liotta R, Traina M.
PMID: 26327921
Therap Adv Gastroenterol. 2015 Sep;8(5):313-5. doi: 10.1177/1756283X15582140.

No abstract available.

Cite
Curcio G, Ligresti D, Granata A, et al. Grasping forceps assisted endoloop/snare polypectomy of a giant duodenal hamartoma. Therap Adv Gastroenterol. 2015;8(5):313-5doi: 10.1177/1756283X15582140.
Curcio, G., Ligresti, D., Granata, A., Tarantino, I., Barresi, L., Liotta, R., & Traina, M. (2015). Grasping forceps assisted endoloop/snare polypectomy of a giant duodenal hamartoma. Therapeutic advances in gastroenterology, 8(5), 313-5. https://doi.org/10.1177/1756283X15582140
Curcio, Gabriele, et al. "Grasping forceps assisted endoloop/snare polypectomy of a giant duodenal hamartoma." Therapeutic advances in gastroenterology vol. 8,5 (2015): 313-5. doi: https://doi.org/10.1177/1756283X15582140
Curcio G, Ligresti D, Granata A, Tarantino I, Barresi L, Liotta R, Traina M. Grasping forceps assisted endoloop/snare polypectomy of a giant duodenal hamartoma. Therap Adv Gastroenterol. 2015 Sep;8(5):313-5. doi: 10.1177/1756283X15582140. PMID: 26327921; PMCID: PMC4530430.
Copy Download .nbib Format: NLM
Preoperative hematocrit concentration and the risk of stroke in patients undergoing isolated coronary-artery bypass grafting.

Anemia

Musallam KM, Jamali FR, Rosendaal FR, Richards T, Spahn DR, Khavandi K, Barakat I, Demoss B, Lotta LA, Peyvandi F, Sfeir PM.
PMID: 23738059
Anemia. 2013;2013:206829. doi: 10.1155/2013/206829. Epub 2013 Apr 30.

Background. Identification and management of risk factors for stroke following isolated coronary artery bypass grafting (CABG) could potentially lower the risk of such serious morbidity. Methods. We retrieved data for 30-day stroke incidence and perioperative variables for patients undergoing...

Cite
Musallam KM, Jamali FR, Rosendaal FR, et al. Preoperative hematocrit concentration and the risk of stroke in patients undergoing isolated coronary-artery bypass grafting. Anemia. 2013;2013:206829doi: 10.1155/2013/206829.
Musallam, K. M., Jamali, F. R., Rosendaal, F. R., Richards, T., Spahn, D. R., Khavandi, K., Barakat, I., Demoss, B., Lotta, L. A., Peyvandi, F., & Sfeir, P. M. (2013). Preoperative hematocrit concentration and the risk of stroke in patients undergoing isolated coronary-artery bypass grafting. Anemia, 2013206829. https://doi.org/10.1155/2013/206829
Musallam, Khaled M, et al. "Preoperative hematocrit concentration and the risk of stroke in patients undergoing isolated coronary-artery bypass grafting." Anemia vol. 2013 (2013): 206829. doi: https://doi.org/10.1155/2013/206829
Musallam KM, Jamali FR, Rosendaal FR, Richards T, Spahn DR, Khavandi K, Barakat I, Demoss B, Lotta LA, Peyvandi F, Sfeir PM. Preoperative hematocrit concentration and the risk of stroke in patients undergoing isolated coronary-artery bypass grafting. Anemia. 2013;2013:206829. doi: 10.1155/2013/206829. Epub 2013 Apr 30. PMID: 23738059; PMCID: PMC3657438.
Copy Download .nbib Format: NLM
Protein pathway analysis in Clinical Proteomics using protein microarrays.

Drug discovery today. Technologies

Geho DH, Espina V, Wulfkuhle J, Petricoin EF, Liotta LA.
PMID: 24982012
Drug Discov Today Technol. 2005;2(4):353-9. doi: 10.1016/j.ddtec.2005.11.008.

Molecular diagnostics research within the field of cancer is increasingly focused on detecting low-abundance protein endpoints that can be used to define a patient's disease more completely. Protein microarrays represent an important Clinical Proteomics tool for directly measuring protein...

Cite
Geho DH, Espina V, Wulfkuhle J, et al. Protein pathway analysis in Clinical Proteomics using protein microarrays. Drug Discov Today Technol. 2005;2(4):353-9doi: 10.1016/j.ddtec.2005.11.008.
Geho, D. H., Espina, V., Wulfkuhle, J., Petricoin, E. F., & Liotta, L. A. (2005). Protein pathway analysis in Clinical Proteomics using protein microarrays. Drug discovery today. Technologies, 2(4), 353-9. https://doi.org/10.1016/j.ddtec.2005.11.008
Geho, David H, et al. "Protein pathway analysis in Clinical Proteomics using protein microarrays." Drug discovery today. Technologies vol. 2,4 (2005): 353-9. doi: https://doi.org/10.1016/j.ddtec.2005.11.008
Geho DH, Espina V, Wulfkuhle J, Petricoin EF, Liotta LA. Protein pathway analysis in Clinical Proteomics using protein microarrays. Drug Discov Today Technol. 2005;2(4):353-9. doi: 10.1016/j.ddtec.2005.11.008. PMID: 24982012.
Copy Download .nbib Format: NLM
STUDENTJAMA. Molecular technologies for personalized cancer management.

JAMA

Hasan RK, Wulfkuhle JD, Liotta LA, Petricoin EF.
PMID: 15069056
JAMA. 2004 Apr 07;291(13):1644-5. doi: 10.1001/jama.291.13.1644.

No abstract available.

Cite
Hasan RK, Wulfkuhle JD, Liotta LA, et al. STUDENTJAMA. Molecular technologies for personalized cancer management. JAMA. 2004;291(13):1644-5doi: 10.1001/jama.291.13.1644.
Hasan, R. K., Wulfkuhle, J. D., Liotta, L. A., & Petricoin, E. F. (2004). STUDENTJAMA. Molecular technologies for personalized cancer management. JAMA, 291(13), 1644-5. https://doi.org/10.1001/jama.291.13.1644
Hasan, Rani K, et al. "STUDENTJAMA. Molecular technologies for personalized cancer management." JAMA vol. 291,13 (2004): 1644-5. doi: https://doi.org/10.1001/jama.291.13.1644
Hasan RK, Wulfkuhle JD, Liotta LA, Petricoin EF. STUDENTJAMA. Molecular technologies for personalized cancer management. JAMA. 2004 Apr 07;291(13):1644-5. doi: 10.1001/jama.291.13.1644. PMID: 15069056.
Copy Download .nbib Format: NLM
Use and recovery of a homogeneous catalyst with carbon dioxide as a solubility switch.

Chemical communications (Cambridge, England)

Ablan CD, Hallett JP, West KN, Jones RS, Eckert CA, Liotta CL, Jessop PG.
PMID: 14703813
Chem Commun (Camb). 2003 Dec 21;(24):2972-3. doi: 10.1039/b311146f.

A method for fluorous biphasic catalysis is described,in which the fluorous liquid is replaced by fluorinated silica, the fluorous catalyst is induced to dissolve in the organic solvent by the presence of CO2, and the recovery of the catalyst...

Cite
Ablan CD, Hallett JP, West KN, et al. Use and recovery of a homogeneous catalyst with carbon dioxide as a solubility switch. Chem Commun (Camb). 2003;(24):2972-3doi: 10.1039/b311146f.
Ablan, C. D., Hallett, J. P., West, K. N., Jones, R. S., Eckert, C. A., Liotta, C. L., & Jessop, P. G. (2003). Use and recovery of a homogeneous catalyst with carbon dioxide as a solubility switch. Chemical communications (Cambridge, England), (24), 2972-3. https://doi.org/10.1039/b311146f
Ablan, Christopher D, et al. "Use and recovery of a homogeneous catalyst with carbon dioxide as a solubility switch." Chemical communications (Cambridge, England) vol. ,24 (2003): 2972-3. doi: https://doi.org/10.1039/b311146f
Ablan CD, Hallett JP, West KN, Jones RS, Eckert CA, Liotta CL, Jessop PG. Use and recovery of a homogeneous catalyst with carbon dioxide as a solubility switch. Chem Commun (Camb). 2003 Dec 21;(24):2972-3. doi: 10.1039/b311146f. PMID: 14703813.
Copy Download .nbib Format: NLM
Alpha-cyclodextrin functionalized CdS nanocrystals for fabrication of 2/3 D assemblies.

The journal of physical chemistry. B

Depalo N, Comparelli R, Striccoli M, Curri ML, Fini P, Giotta L, Agostiano A.
PMID: 16942075
J Phys Chem B. 2006 Sep 07;110(35):17388-99. doi: 10.1021/jp062764s.

Different types of cyclodextrins (CDs) have been tested as mediators for the water phase transfer of organic-capped CdS nanocrystals (NCs), and alphaCD has been demonstrated to be the most effective system. The formation of a complex based on alphaCDs...

Cite
Depalo N, Comparelli R, Striccoli M, et al. Alpha-cyclodextrin functionalized CdS nanocrystals for fabrication of 2/3 D assemblies. J Phys Chem B. 2006;110(35):17388-99doi: 10.1021/jp062764s.
Depalo, N., Comparelli, R., Striccoli, M., Curri, M. L., Fini, P., Giotta, L., & Agostiano, A. (2006). Alpha-cyclodextrin functionalized CdS nanocrystals for fabrication of 2/3 D assemblies. The journal of physical chemistry. B, 110(35), 17388-99. https://doi.org/10.1021/jp062764s
Depalo, Nicoletta, et al. "Alpha-cyclodextrin functionalized CdS nanocrystals for fabrication of 2/3 D assemblies." The journal of physical chemistry. B vol. 110,35 (2006): 17388-99. doi: https://doi.org/10.1021/jp062764s
Depalo N, Comparelli R, Striccoli M, Curri ML, Fini P, Giotta L, Agostiano A. Alpha-cyclodextrin functionalized CdS nanocrystals for fabrication of 2/3 D assemblies. J Phys Chem B. 2006 Sep 07;110(35):17388-99. doi: 10.1021/jp062764s. PMID: 16942075.
Copy Download .nbib Format: NLM
Treatment of descending thoracic aneurysm with an intraaortic occluder.

Texas Heart Institute journal

Liotta D, Frank L, del Rio M, Gallo A, Navia J, Bertolozzi E, Bracco D, Cesareo V.
PMID: 15229741
Tex Heart Inst J. 1987 Jun;14(2):196-204; discussion 204-5.

Elective treatment of descending thoracic aneurysms involves direct surgery, with Dacron graft replacement of the diseased aortic segment. When the patient's condition contraindicates major surgery, however, the surgeon should consider using an extraanatomic approach-implanting an ascending aorta-to-abdominal aorta Dacron...

Cite
Liotta D, Frank L, del Rio M, et al. Treatment of descending thoracic aneurysm with an intraaortic occluder. Tex Heart Inst J. 1987;14(2):196-204; discussion 204-5
Liotta, D., Frank, L., del Rio, M., Gallo, A., Navia, J., Bertolozzi, E., Bracco, D., & Cesareo, V. (1987). Treatment of descending thoracic aneurysm with an intraaortic occluder. Texas Heart Institute journal, 14(2), 196-204; discussion 204-5.
Liotta, D, et al. "Treatment of descending thoracic aneurysm with an intraaortic occluder." Texas Heart Institute journal vol. 14,2 (1987): 196-204; discussion 204-5.
Liotta D, Frank L, del Rio M, Gallo A, Navia J, Bertolozzi E, Bracco D, Cesareo V. Treatment of descending thoracic aneurysm with an intraaortic occluder. Tex Heart Inst J. 1987 Jun;14(2):196-204; discussion 204-5. PMID: 15229741; PMCID: PMC324721.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 462 entries